AssetMark’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
AssetMark's CRSP Position: Q3 2026 in Review
AssetMark reduced its CRISPR Therapeutics (CRSP) stake by 26% in Q3 2026, selling an estimated $1.89K and leaving 99 shares worth $5.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2745.
AssetMark first reported a position in CRSP in Q1 2022 and has held it in 11 quarters since. The position peaked at $7.31K in Q2 2026. 422 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- AssetMark held 99 shares of CRISPR Therapeutics worth $5.48K as of Q3 2026.
- AssetMark sold 35 CRISPR Therapeutics shares in Q3 2026, an estimated $1.89K.
- CRISPR Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2745 holding.
- AssetMark first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 11 quarters since.
- AssetMark's CRISPR Therapeutics position peaked at $7.31K in Q2 2026.
- 422 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.